CTMX logo

CytomX Therapeutics (CTMX) Company Overview

Profile

Full Name:

CytomX Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 8, 2015

Indexes:

Not included

Description:

CytomX Therapeutics (CTMX) is a biotechnology company focused on developing innovative cancer therapies. They use a unique technology called Probody™ to create treatments that target tumors while sparing healthy tissue, aiming to improve the effectiveness and safety of cancer treatments.

Key Details

Price

$0.84

Annual Revenue

$101.21 M(+90.38% YoY)

Annual EPS

-$0.01(+99.34% YoY)

Beta

0.61

Events Calendar

Earnings

Next earnings date:

Mar 11, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 11, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 7, 25 HC Wainwright & Co.
Neutral
Nov 11, 24 HC Wainwright & Co.
Neutral
Sep 13, 24 HC Wainwright & Co.
Neutral
Aug 22, 24 HC Wainwright & Co.
Neutral
Jun 27, 24 HC Wainwright & Co.
Neutral
May 28, 24 Piper Sandler
Overweight
May 9, 24 Wedbush
Outperform
May 9, 24 HC Wainwright & Co.
Neutral
May 9, 24 BMO Capital
Market Perform
May 6, 24 Jefferies
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
CTMX
zacks.comJanuary 7, 2025

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
CTMX
globenewswire.comJanuary 6, 2025

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CTMX
zacks.comDecember 16, 2024

CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CTMX
globenewswire.comNovember 27, 2024

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CTMX
globenewswire.comSeptember 9, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CTMX
globenewswire.comJune 18, 2024

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
CTMX
globenewswire.comJune 17, 2024

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

Buy Alert: 3 Penny Stocks That Will Explode in 2024
Buy Alert: 3 Penny Stocks That Will Explode in 2024
Buy Alert: 3 Penny Stocks That Will Explode in 2024
CTMX
investorplace.comJune 5, 2024

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.

CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics Announces New Employment Inducement Grants
CytomX Therapeutics Announces New Employment Inducement Grants
CTMX
globenewswire.comMay 16, 2024

On May 15, 2024, CytomX Therapeutics, Inc. (Nasdaq: CTMX) granted two new employees options to buy a total of 130,000 shares of the company's common stock at an exercise price of $1.96 per share, matching the closing price on the date of the grants.

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CTMX
Zacks Investment ResearchMay 2, 2024

CytomX Therapeutics (CTMX) experienced a surge in its stock price during the last trading session, accompanied by higher-than-average trading volume. However, the most recent changes in earnings estimates for the company do not indicate continued growth in the future.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for CytomX Therapeutics?
  • Does CytomX Therapeutics pay dividends?
  • What sector is CytomX Therapeutics in?
  • What industry is CytomX Therapeutics in?
  • What country is CytomX Therapeutics based in?
  • When did CytomX Therapeutics go public?
  • Is CytomX Therapeutics in the S&P 500?
  • Is CytomX Therapeutics in the NASDAQ 100?
  • Is CytomX Therapeutics in the Dow Jones?
  • When was CytomX Therapeutics's last earnings report?
  • When does CytomX Therapeutics report earnings?
  • Should I buy CytomX Therapeutics stock now?

What is the ticker symbol for CytomX Therapeutics?

The ticker symbol for CytomX Therapeutics is NASDAQ:CTMX

Does CytomX Therapeutics pay dividends?

No, CytomX Therapeutics does not pay dividends

What sector is CytomX Therapeutics in?

CytomX Therapeutics is in the Healthcare sector

What industry is CytomX Therapeutics in?

CytomX Therapeutics is in the Biotechnology industry

What country is CytomX Therapeutics based in?

CytomX Therapeutics is headquartered in United States

When did CytomX Therapeutics go public?

CytomX Therapeutics's initial public offering (IPO) was on October 8, 2015

Is CytomX Therapeutics in the S&P 500?

No, CytomX Therapeutics is not included in the S&P 500 index

Is CytomX Therapeutics in the NASDAQ 100?

No, CytomX Therapeutics is not included in the NASDAQ 100 index

Is CytomX Therapeutics in the Dow Jones?

No, CytomX Therapeutics is not included in the Dow Jones index

When was CytomX Therapeutics's last earnings report?

CytomX Therapeutics's most recent earnings report was on Nov 7, 2024

When does CytomX Therapeutics report earnings?

The next expected earnings date for CytomX Therapeutics is Mar 11, 2025

Should I buy CytomX Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions